↓ Skip to main content

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

Overview of attention for article published in Supportive Care in Cancer, June 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

policy
1 policy source
twitter
4 X users

Citations

dimensions_citation
60 Dimensions

Readers on

mendeley
110 Mendeley
Title
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Published in
Supportive Care in Cancer, June 2015
DOI 10.1007/s00520-015-2809-3
Pubmed ID
Authors

Yolanda Escobar, Gerardo Cajaraville, Juan Antonio Virizuela, Rosa Álvarez, Andrés Muñoz, Olatz Olariaga, María José Tamés, Begoña Muros, María Jose Lecumberri, Jaime Feliu, Purificación Martínez, Juan Carlos Adansa, María José Martínez, Rafael López, Ana Blasco, Pere Gascón, Virginia Calvo, Pablo Luna, Joaquín Montalar, Patricia Del Barrio, María Victoria Tornamira

Abstract

This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints. Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients' diary. Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 109 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 14%
Student > Bachelor 14 13%
Other 13 12%
Researcher 7 6%
Student > Postgraduate 6 5%
Other 21 19%
Unknown 34 31%
Readers by discipline Count As %
Medicine and Dentistry 25 23%
Nursing and Health Professions 15 14%
Pharmacology, Toxicology and Pharmaceutical Science 11 10%
Biochemistry, Genetics and Molecular Biology 8 7%
Agricultural and Biological Sciences 4 4%
Other 7 6%
Unknown 40 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2018.
All research outputs
#5,935,490
of 23,905,714 outputs
Outputs from Supportive Care in Cancer
#1,343
of 4,783 outputs
Outputs of similar age
#65,743
of 267,038 outputs
Outputs of similar age from Supportive Care in Cancer
#17
of 77 outputs
Altmetric has tracked 23,905,714 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,783 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,038 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.